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Thomas Alva Edison, an American inventor, scientist and busi-
nessman: If we all did the things we are capable of, we would astound 
ourselves.
Sudden cardiac death (SCD) is the most common lethal mani-
festation of heart disease, and in many cases it is the descent’s first 
and only symptom1-3. SCD is defined as “unexpected natural death 
from a cardiac cause within a short time period, generally ≤ 1 hour 
from the onset of symptoms, in a person without any prior condition 
that would appear fatal”3. Actually, clinical and pathologic findings 
suggest that patients with conditions such as coronary artery  disease, 
cardiomyopathy, cardiac rhythm disturbances, or hypertensive 
heart disease are at high risk of SCD4,3. From epidemiological point 
of view, the current annual incidence of SCD in the United States 
(total population approximately 300 000 000) would range between 
180 000 and 250 000 cases per year. For the world (total population 
approximately 6 540 000 000), the estimated annual burden of SCD 
would be in the range of 4 to 5 million cases per year5. Due to this 
scenario, SCD is considered a major unsolved problem in clinical 
cardiology, emergency medicine, and public health system3.
Transiting the field of schizophrenia, the topic of SCD should 
not be overlooked. With this in mind, a series of data could be put 
forward to explain it.
Although schizophrenia has been considered a distinct disease en-
tity for many decades, its precise definition and etio-pathophysiology 
remain obscure and its treatment remains unsatisfactory. Schizo-
phrenia is increasingly being viewed as a neurodevelopment disorder 
likely multi-factorial in origin6. In these aspects, schizophrenia is a 
chronic and devastating brain disease characterized by a collection 
of signs and symptoms such as psychosis, severe impairments in 
cognition, behavior and affect, as well as impairments in the ability 
to work, have a family and socialize7,8.
Whereas pharmacotherapy is still considered an important 
approach to treating schizophrenia, many patients continue quite 
symptomatic and remain cognitively and functionally impaired 
despite optimal treatment. Indeed, approximately 30% of individuals 
with schizophrenia exhibit little or no improvements with antipsy-
chotics9. This problem of minimal improvement in multiple symptom 
and functional domains despite contemporary treatments is further 
compounded by the fact that patients with schizophrenia have a 
high rate of premature death compared with the general popula-
tion. Studies have found that individuals with schizophrenia have a 
two to three-fold greater risk of premature death than individuals 
without schizophrenia. It has been hypothesized that this increased 
risk of early death may be due to many factors including life style, 
suicide (in particular in young male patients within the first decade 
after diagnosis), early development of cardiovascular disease, and 
high prevalence of metabolic syndrome and carbohydrate and lipid 
metabolic disorders. An equally and unfortunately deemphasized 
cause of premature death in patients with schizophrenia is sudden 
cardiac death7,10-15. In these lines, understanding the mechanisms and 
possible causal factors behind sudden cardiac death in individuals 
with schizophrenia is crucial for establishing preventive measures. 
There is evidence that cardiovascular dysfunction is directly 
associated with the occurrence of abrupt fatal events in these indi-
viduals13,14,16. First, some antipsychotics have been associated with 
cardiovascular adverse events (e.g., QT interval prolongation), sug-
gesting that this could lead to torsade the points or sudden death in 
schizophrenia patients13-17. Second, several antipsychotic agents are 
associated with metabolic dysfunction, including diabetes mellitus, 
increased triglyceride levels and weight gain, all of these factors 
have been associated with increased cardiovascular risk16,18,19. Third, 
antipsychotic treatment has been linked with alterations in blood 
pressure and heart rate, among which orthostatic hypotension, with 
or without syncope, is relatively common16,20,21. Fourth, smoking is 
also considered an important risk factor for sudden cardiac death 
in people with schizophrenia and the effects of smoking on cardiac 
system may be due to an increase in platelet adhesiveness and release 
of cathecholamines7,22.
Despite scientific advances in recent decades, it has been ex-
tremely difficult to prevent the occurrence of sudden cardiac death 
in individuals with schizophrenia, largely because there have been 
no concerted or coordinated efforts to address this major public 
health problem. One possibility would be to emulate successful 
programs in other areas of medicine towards the area of sudden 
cardiac death. For example, the sudden unexpected death in epilepsy 
(SUDEP) research program developed by Devinsky and Friedman 
in 2011 has been successful program in reducing premature death 
from epilepsy23,24. Implementing a similar program in patients with 
schizophrenia would be with the goal of reducing or even preventing 
sudden cardiac death in schizophrenia. Such efforts would include: 
(1) Clinical and research collaborations to incorporate the expertise 
and knowledge of various medical and research specialties and other 
health related areas. These collaborations would hopefully culminate 
into multidisciplinary research which is essential for developing novel 
therapeutics, unraveling the mechanisms of premature cardiac death, 
and identifying specific causal factors and preventive measures to 
minimize the occurrence of sudden cardiac death in schizophrenia. 
(2) Create data collection systems to obtain prospective data from 
treatment centers, clinicians, patients and their families. These data 
can then be further analyzed to identify risk factors for the occurrence 
of sudden cardiac death in schizophrenia thus producing a direct 
measure of risk. Furthermore, it would be appropriate to develop 
additional prospective studies in reference centers in psychiatry using 
cardiac physiological parameters to try to assess more precisely our 
understanding of the cardiovascular alterations that affect individuals 
with schizophrenia in order to reverse or avoid a fatal cardiac event. 
(3) Preclinical studies could be conducted to better understand risk 
factors, mechanisms, causes and preventive measures. Due to the 
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difficulty in establishing the precise cause or causes of sudden cardiac 
death in schizophrenia, animal models may be a suitable model for 
investigating possible underlying pathophysiological mechanisms25. 
It would be then important to integrate these findings from basic 
science with clinical studies also known as “bench-to-bedside” re-
search26. (4) Implement interventions prospectively which resulted 
from the above efforts to determine their utility in preventing the 
occurrence of cardiovascular changes that may culminate in sudden 
death in individuals with schizophrenia. Clearly, it would be para-
mount that these procedures be instituted when the initial diagnosis 
of schizophrenia is made.
Currently, our understanding of the best strategies in preventing 
sudden cardiac death in schizophrenia is still in its infancy. Initial 
data suggests that preventative measures other than medical thera-
pies could be useful in reducing the risk of sudden cardiac death 
in schizophrenia9, although strict evidence for their effectiveness 
is still lacking. 
Although we have not tabulated epidemiological data on cases 
of SCD in individuals with schizophrenia in our facility, many of our 
psychiatrists have reported the occurrence of fatal events among our 
patients, reinforcing that schizophrenia-related mortality, particularly 
sudden cardiac death, is a significant public health concern at a global 
level. It is crucial that a concerted and collaborative approach be 
implemented to tackle this worrisome problem. Based on the success 
of the SUDEP23,24 program, we believe that a similar program could be 
instituted for reducing the risk of or preventing sudden cardiac death 
in patients with schizophrenia. Resulting data from this program 
could then be prospectively tested in patients with schizophrenia 
to determine their effectiveness in preventing or minimizing the 
occurrence of sudden cardiac death. 
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